Adragos Pharma, a pharmaceutical contract development organization, completed the acquisition of Lamda Laboratories, an innovative contract development company that focus on providing quality research for Generic and Generic-plus developments, from Clinigen, a pharmaceutical services company focused on providing ethical access to medicines. Financial terms were not disclosed. "We are pleased to have carried out this acquisition. Lamda is of great importance to us because it extends our value chain coverage from pure Manufacturing to Development, allowing us to address a new customer group. At the same time, we can offer existing Lamda customers production capacity within the Adragos Group and existing Adragos Manufacturing customers a broader service offering," Andreas Raabe, Adragos Pharma CEO.